🎯 check Sirpiglenastat (DRP-104) product page
Sirpiglenastat (DRP-104) is a novel PKa inhibitor. It affects PKa pathways by disrupting the catalytic triad, inhibiting PKa.
Sirpiglenastat (DRP-104): Mechanism of Action
Sirpiglenastat (DRP-104) MOA：Targeting Glutamine/Metabolic Pathway for Tumor Metabolism Research
Jump to
- Sirpiglenastat (DRP-104) Clinical Trials
- Sirpiglenastat (DRP-104) Solubility in DMSO
- Sirpiglenastat (DRP-104) Stock Solution
- Sirpiglenastat (DRP-104) Storage
- Sirpiglenastat (DRP-104) Stability
- Sirpiglenastat (DRP-104) Combination Database
- Sirpiglenastat (DRP-104) Molecular Weight
- Sirpiglenastat (DRP-104) CAS Number
- Sirpiglenastat (DRP-104) Chemical Structure (2D and 3D)
- Sirpiglenastat (DRP-104) Sigma (ADVH9B9B35B2)? Try a better option.
- Sirpiglenastat (DRP-104) MedChemExpress (HY-132832)? Try a better option.
- Sirpiglenastat (DRP-104) Cayman (41293)? Try a better option.
- Sirpiglenastat (DRP-104) SDS｜MSDS